Does the media refer more to PRTA or BDTX?

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Prothena. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 2 mentions for Prothena. Black Diamond Therapeutics' average media sentiment score of 1.80 beat Prothena's score of 1.61 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Black Diamond Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation & earnings, AGMB or BDTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Black Diamond Therapeutics N/A N/A $22.37M -$0.75 N/A

Is AGMB or BDTX more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat Black Diamond Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Black Diamond Therapeutics N/A -32.10% -25.21%

Does the media refer more to AGMB or BDTX?

In the previous week, AgomAb Therapeutics had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 4 mentions for AgomAb Therapeutics and 3 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.80 beat AgomAb Therapeutics' score of 0.72 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Black Diamond Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is BDTX or EVMN more profitable?

Black Diamond Therapeutics' return on equity of -32.10% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -32.10% -25.21% Evommune N/A -62.63% -40.55%

Does the media prefer BDTX or EVMN?

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Evommune. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 2 mentions for Evommune. Black Diamond Therapeutics' average media sentiment score of 1.80 beat Evommune's score of 0.89 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Evommune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CCCC or BDTX?

In the previous week, C4 Therapeutics had 2 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 5 mentions for C4 Therapeutics and 3 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.80 beat C4 Therapeutics' score of 1.11 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Black Diamond Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Black Diamond Therapeutics (BDTX) Competitors

$2.23 -0.04 (-1.76%)

As of 08/28/2026 04:00 PM Eastern

Compare

BDTX vs. PRTA, AGMB, EVMN, CCCC, and KMDA

Should you buy Black Diamond Therapeutics stock or one of its competitors? Black Diamond Therapeutics's main competitors and comparable companies include Prothena (PRTA), AgomAb Therapeutics (AGMB), Evommune (EVMN), C4 Therapeutics (CCCC), and Kamada (KMDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Black Diamond Therapeutics compare to Prothena?

Prothena (NASDAQ:PRTA) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Prothena has a beta of -0.3, indicating that its share price is 130% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.28, indicating that its share price is 228% more volatile than the broader market.

Black Diamond Therapeutics has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	50.46	-$244.09M	-$0.84	N/A
Black Diamond Therapeutics	N/A	N/A	$22.37M	-$0.75	N/A

97.1% of Prothena shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 10.4% of Prothena shares are owned by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Prothena. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 2 mentions for Prothena. Black Diamond Therapeutics' average media sentiment score of 1.80 beat Prothena's score of 1.61 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Black Diamond Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Black Diamond Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

Prothena presently has a consensus price target of $24.57, suggesting a potential upside of 163.36%. Black Diamond Therapeutics has a consensus price target of $9.80, suggesting a potential upside of 339.46%. Given Black Diamond Therapeutics' higher possible upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Black Diamond Therapeutics beats Prothena on 9 of the 16 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

In the previous week, AgomAb Therapeutics had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 4 mentions for AgomAb Therapeutics and 3 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.80 beat AgomAb Therapeutics' score of 0.72 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Black Diamond Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

AgomAb Therapeutics' return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

AgomAb Therapeutics presently has a consensus price target of $37.50, indicating a potential upside of 184.74%. Black Diamond Therapeutics has a consensus price target of $9.80, indicating a potential upside of 339.46%. Given Black Diamond Therapeutics' higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than AgomAb Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Black Diamond Therapeutics	N/A	N/A	$22.37M	-$0.75	N/A

Summary

Black Diamond Therapeutics beats AgomAb Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Evommune?

Black Diamond Therapeutics (NASDAQ:BDTX) and Evommune (NYSE:EVMN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Black Diamond Therapeutics' return on equity of -32.10% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
Evommune	N/A	-62.63%	-40.55%

Black Diamond Therapeutics has higher earnings, but lower revenue than Evommune. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	N/A	N/A	$22.37M	-$0.75	N/A
Evommune	$13M	36.43	-$68.87M	-$11.03	N/A

95.5% of Black Diamond Therapeutics shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by company insiders. Comparatively, 31.1% of Evommune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Black Diamond Therapeutics presently has a consensus price target of $9.80, suggesting a potential upside of 339.46%. Evommune has a consensus price target of $41.56, suggesting a potential upside of 218.43%. Given Black Diamond Therapeutics' higher probable upside, equities research analysts clearly believe Black Diamond Therapeutics is more favorable than Evommune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Evommune	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Evommune. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 2 mentions for Evommune. Black Diamond Therapeutics' average media sentiment score of 1.80 beat Evommune's score of 0.89 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Evommune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Black Diamond Therapeutics beats Evommune on 8 of the 14 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to C4 Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Black Diamond Therapeutics has lower revenue, but higher earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.04M	13.52	-$104.99M	-$1.00	N/A
Black Diamond Therapeutics	N/A	N/A	$22.37M	-$0.75	N/A

Black Diamond Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -289.44%. Black Diamond Therapeutics' return on equity of -32.10% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-289.44%	-45.45%	-30.90%
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

C4 Therapeutics presently has a consensus price target of $7.75, indicating a potential upside of 101.30%. Black Diamond Therapeutics has a consensus price target of $9.80, indicating a potential upside of 339.46%. Given Black Diamond Therapeutics' higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

C4 Therapeutics has a beta of 2.91, meaning that its stock price is 191% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.28, meaning that its stock price is 228% more volatile than the broader market.

In the previous week, C4 Therapeutics had 2 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 5 mentions for C4 Therapeutics and 3 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.80 beat C4 Therapeutics' score of 1.11 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Black Diamond Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Black Diamond Therapeutics beats C4 Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Kamada?

Kamada (NASDAQ:KMDA) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Black Diamond Therapeutics has lower revenue, but higher earnings than Kamada. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.64	$20.20M	$0.38	21.82
Black Diamond Therapeutics	N/A	N/A	$22.37M	-$0.75	N/A

Kamada presently has a consensus target price of $13.00, indicating a potential upside of 56.82%. Black Diamond Therapeutics has a consensus target price of $9.80, indicating a potential upside of 339.46%. Given Black Diamond Therapeutics' higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Black Diamond Therapeutics had 2 more articles in the media than Kamada. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 1 mentions for Kamada. Kamada's average media sentiment score of 1.89 beat Black Diamond Therapeutics' score of 1.80 indicating that Kamada is being referred to more favorably in the media.

Company	Overall Sentiment
Kamada	Very Positive
Black Diamond Therapeutics	Very Positive

Kamada has a net margin of 11.60% compared to Black Diamond Therapeutics' net margin of 0.00%. Kamada's return on equity of 8.37% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.60%	8.37%	5.85%
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

20.4% of Kamada shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kamada has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.28, indicating that its stock price is 228% more volatile than the broader market.

Summary

Kamada beats Black Diamond Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Black Diamond Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDTX vs. The Competition

Export

Metric	Black Diamond Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$128.12M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-2.97	11.62	273.16	25.45
Price / Sales	N/A	1,396.16	640.19	89.89
Price / Cash	4.23	106.39	76.74	53.00
Price / Book	1.34	16.53	12.98	6.14
Net Income	$22.37M	-$22.80M	$3.48B	$348.86M
7 Day Performance	0.90%	-0.31%	0.13%	-0.80%
1 Month Performance	30.03%	9.80%	7.08%	4.13%
1 Year Performance	-18.91%	55.66%	24.67%	15.17%

Black Diamond Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDTX Black Diamond Therapeutics	2.5841 of 5 stars	$2.23 -1.8%	$9.80 +339.5%	-18.9%	$128.12M	N/A	N/A	90	Positive News
PRTA Prothena	2.8928 of 5 stars	$9.35 +2.9%	$24.57 +162.8%	+13.8%	$489.50M	$54.53M	N/A	130	Positive News
AGMB AgomAb Therapeutics	3.6202 of 5 stars	$13.37 -3.4%	$37.50 +180.5%	N/A	$484.49M	N/A	N/A	62	News Coverage Analyst Forecast
EVMN Evommune	2.9235 of 5 stars	$13.34 -1.0%	$41.56 +211.5%	N/A	$484.11M	$13M	N/A	45	Analyst Forecast
CCCC C4 Therapeutics	1.6784 of 5 stars	$3.92 -4.4%	$7.75 +97.7%	+48.1%	$482.28M	$35.95M	N/A	150	Positive News Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDTX) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Black Diamond Therapeutics (BDTX) Competitors

BDTX vs. PRTA, AGMB, EVMN, CCCC, and KMDA

How does Black Diamond Therapeutics compare to Prothena?

Summary

How does Black Diamond Therapeutics compare to AgomAb Therapeutics?

Summary

How does Black Diamond Therapeutics compare to Evommune?

Summary

How does Black Diamond Therapeutics compare to C4 Therapeutics?

Summary

How does Black Diamond Therapeutics compare to Kamada?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX vs. The Competition

Black Diamond Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Black Diamond Therapeutics (BDTX) Competitors

BDTX vs. PRTA, AGMB, EVMN, CCCC, and KMDA

How does Black Diamond Therapeutics compare to Prothena?

Which has more volatility & risk, PRTA or BDTX?

Which has better earnings & valuation, PRTA or BDTX?

Do institutionals and insiders hold more shares of PRTA or BDTX?

Does the media refer more to PRTA or BDTX?

Is PRTA or BDTX more profitable?

Do analysts rate PRTA or BDTX?

Summary

How does Black Diamond Therapeutics compare to AgomAb Therapeutics?

Does the media refer more to AGMB or BDTX?

Is AGMB or BDTX more profitable?

Do insiders & institutionals have more ownership in AGMB or BDTX?

Do analysts rate AGMB or BDTX?

Which has preferable valuation & earnings, AGMB or BDTX?

Summary

How does Black Diamond Therapeutics compare to Evommune?

Is BDTX or EVMN more profitable?

Which has better valuation & earnings, BDTX or EVMN?

Do institutionals & insiders hold more shares of BDTX or EVMN?

Do analysts rate BDTX or EVMN?

Does the media prefer BDTX or EVMN?

Summary

How does Black Diamond Therapeutics compare to C4 Therapeutics?

Which has higher earnings and valuation, CCCC or BDTX?

Is CCCC or BDTX more profitable?

Do institutionals and insiders believe in CCCC or BDTX?

Do analysts prefer CCCC or BDTX?

Which has more volatility and risk, CCCC or BDTX?

Does the media refer more to CCCC or BDTX?

Summary

How does Black Diamond Therapeutics compare to Kamada?

Which has better earnings and valuation, KMDA or BDTX?

Do analysts prefer KMDA or BDTX?

Does the media favor KMDA or BDTX?

Is KMDA or BDTX more profitable?

Do institutionals & insiders believe in KMDA or BDTX?

Which has more volatility & risk, KMDA or BDTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX vs. The Competition

Black Diamond Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools